INTERVENTIONAL CARDIOLOGY 2015 30[™] ANNUAL INTERNATIONAL SYMPOSIUM



Comprehensive Approach to the Percutaneous Management of Structural Heart Disease and Coronary and Peripheral Vascular Disease

COURSE DIRECTOR James R. Margolis, MD, FACC

Endorsed by the California and Colorado Chapters of the American College of Cardiology





The Westin Snowmass Resort, Snowmass Village, Colorado March 1-6, 2015 In January 1984, by serendipity, Andreas Grüntzig and I found ourselves alone in Snowmass for different business reasons. We took the occasion to ski together for two long and wonderful days. On the ski lifts, we talked about many things, but mostly angioplasty, as PCI was called in those days. It was from these discussions that an interventional cardiology meeting in Snowmass was born.

From the outset, the purposes of this meeting were:

- > To explore ways to improve the still young technique, and to expand its reach.
- > To partner with industry in these endeavors.
- > To foster international cooperation and exchange of ideas, an extension of the teaching principles that Grüntzig had initiated seven years earlier.
- > To do all of this in a pleasant environment that encouraged camaraderie as opposed to competition.

The first few meetings were quite small, consisting of didactic presentations and showing of edited videotapes from our live demonstration courses in Miami. But these early meetings adhered closely to our core objectives. It became clear that Snowmass was an excellent venue for the exchange of ideas not only in the lecture hall, but also in social venues and on ski lifts. As the meeting grew in size and stature, the European participation grew proportionately. This is how it was for 15 years.

In 2000, on the advice of Patrick Serruys, we switched to the international format that persists today. It was at this time that we added participation from Japan and Korea. The international format provided an opportunity to better focus on our core values, and to keep the course fresh with a healthy turnover of young, previously undiscovered faculty and exposure to ideas and methodologies from far off lands. The new format exposed attendees to cutting edge work performed both in and outside the U.S. More importantly, with faculty from more than 25 countries on five continents the audience gained a perspective of how differing socioeconomic factors alter the performance of PCI in different cultures and different countries – usually achieving comparable results.

Finally, the international format fosters, albeit in a small way, behavior conducive to world peace. In these turbulent times, academic and scientific exchanges may be useful in counteracting the rhetoric and irresponsible actions of world leaders.

This year we will continue to passionately adhere to our mission while presenting an exciting didactic program combined with a celebration of thirty wonderful years in Snowmass. We will look back to see where we have been while exploring where we are going. As course director, I have had the honor and great pleasure of interacting with so many brilliant and fascinating individuals that this interaction by itself would have made it all worthwhile. During the meeting, I will introduce you to these people and recognize their contributions. Please join us for a fascinating ride from the past to the future and all that in between.

James R. Margolis, MD, FACC Course Director

CALL FOR ABSTRACTS: SUBMISSION DUE DATE JANUARY 16, 2015

Submissions of original abstracts are being accepted for oral presentation and electronic poster display. To submit your abstracts, please visit www.promedicacme.com.

KEY THEMES FOR 2015

Without a doubt, TAVR is the most exciting advance in interventional cardiology in recent years. Not only does the procedure work, it has been proven conclusively that it saves lives. Newer valves and newer iterations of older valves have made the procedure easier, safer and available to a rapidly expanding patient population. This year, we have devoted a major portion of our program to TAVR with more than 30 talks from operators with a combined experience of thousands of cases. These talks cover global experience, patient selection, techniques, avoidance and treatment of complications and discussion of various valves both on the market and those in clinical evaluation. Included is a seven talk mini-symposium on the Achilles heel of TAVR, neurological complications. The symposium concludes with a discussion of modalities for TVT of the mitral valve.

A minor but important theme of the 2015 meeting is devoted to discussion of the meaning of one or more negative studies of treatment modalities that physicians believe are effective, despite a lack of 1A evidence. Talks in this genre start out with the title: "Is the Data Right and the Doctor Wrong, or Vice Versa?"

LEARNING OBJECTIVES

Upon completion of this symposium, participants should be able to:

- > Better understand the meaning of negative studies.
- > Gain a comprehensive picture of TAVR.
- > Integrate advances in electrophysiology into their practice.
- > Better manage complications of coronary and peripheral percutaneous interventions.
- > Discuss the controversies surrounding the indication for coronary stents, efficacy, and complications.
- > Gain an international perspective of percutaneous interventions including the effect of a country's economics on how interventions are performed.

CME ACCREDITATION AND DESIGNATION



Promedica International CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Promedica International CME designates this live activity for a maximum of 30.5 AMA PRA Category 1 Credit(sTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider approved by the California Board of Registered Nursing, Provider #8495 for 30.5 contact hours.

Category 1 CEUs for Perfusionists have been applied for through the American Board of Cardiovascular Perfusion (ABCP).

EUROPEAN ACCREDITATION

Due to a mutual recognition between the AMA and the UEMS, European participants may convert AMA Category 1 Credits.

ACTIVITY EVALUATION

Evaluation by online questionnaire will address content, presentation and future educational needs.

COMMERCIAL SUPPORT

This program is supported, in part, by educational grants and exhibits from industry, in accordance with the ACCME Standards for Commercial Support. At the time of printing, a complete list of commercial supporters was not available. Appropriate acknowledgement will be given to all supporters in meeting materials onsite.

COURSE DIRECTOR

James R. Margolis, MD, FACC USA

COURSE CO-DIRECTORS

Dariusz Dudek, MD, PhD Poland

Osamu Katoh, MD Japan

Jacques J. Koolen, MD, PhD The Netherlands

Martin B. Leon, MD, FACC USA

M. Pauliina Margolis, MD, PhD USA/Finland

Seung-Jung Park, MD, PhD, FACC South Korea

Augusto D. Pichard, MD, FACC USA

Nicolaus Reifart, MD, FACC Germany

SCIENTIFIC COMMITTEE

Jorge Belardi, MD, FACC Argentina

Patrick Kay, MD, PhD New Zealand

Hideo Nishikawa, MD, PhD Japan

Marko Noc, MD, PhD Slovenia

Michael Pieper, MD Switzerland

Kari I. Saunamäki, MD, PhD Denmark

Robert S. Schwartz, MD USA Gerald S. Werner, MD, PhD, FACC

Germany

FACULTY

Kevin Abrams, MD USA Yolande Appelman, MD, PhD The Netherlands

Stanislaw Bartus, MD, PhD Poland

Andreas Baumbach, MD United Kingdom

Diego F. Belardi, MD Argentina

Brian T. Bethea, MD USA

Guus Brueren, MD, PhD The Netherlands Leszek Bryniarski, MD, PhD Poland Matjaz Bunc, MD, PhD Slovenia Mark W. Burket, MD, FACC USA Pawel E. Buszman, MD, PhD, FACC Poland Piotr P. Buszman, MD, PhD Poland David Clark, MBBS Australia Peter Clemmensen, MD, DMSc Denmark Justin Davies, MD, PhD United Kingdom Pieter den Heijer, MD, PhD The Netherlands Willem Dewilde, MD The Netherlands Pieter A. Doevendans, MD, PhD The Netherlands Thomas Engstrøm, MD, PhD, DMSci Denmark Andrjes Erglis, MD, PhD, FACC Latvia Robert J. Gil, MD, PhD Poland Luis Guzmán, MD, FACC USA Michal Hawranek, MD, PhD Poland Timothy D. Henry, MD, FACC USA Richard R. Heuser, MD, FACC USA Gerhard Hindricks, MD, PhD Germany Kurt Huber, MD, FACC Austria Nikolaj Ihlemann, MD, PhD Denmark Charles IIsley, MD United Kingdom David Gareth Jones, BSc(Hons), MBBS, MD(Res) United Kingdom Petr Kala, MD, PhD Czech Republic David Kallend, MBBS USA Anne Kaltoft, MD, PhD Denmark Samir Kapadia, MD, FACC **USA** Sasko Kedev, MD, PhD, FACC Republic of Macedonia

Hyo-Soo Kim, MD, PhD South Korea Young-Hak Kim, MD, PhD South Korea

Karel T. Koch, MD, PhD The Netherlands Bon-Kwon Koo, MD, PhD, FACC South Korea Alexandra Lansky, MD, FACC USA Jens Flensted Lassen, MD, PhD Denmark Seung-Whan Lee, MD, PhD South Korea Jacek Legutko, MD, PhD Poland Maciej Lesiak, MD, PhD Poland Michael J. Mack, MD, FACC USA Raj Makkar, MD, FACC USA Mark Mason, MD United Kingdom Ian Meredith, MBBS, PhD Australia Evgeny Merkulov, MD, PhD Russia Markus Meyer-Gessner, MD Germany Krzysztof Milewski, MD, PhD Poland Vsevolod Mironov, MD Russia Jeffrey W. Moses, MD, FACC USA Blaz Mrevlje, MD Germany Andrzej Ochala, MD Poland Aleksander G. Osiev, MD, PhD Russia Duk-Woo Park, MD, PhD South Korea Radoslaw Parma, MD, PhD Poland Hrvoje Pintarić, MD, PhD Croatia Christopher Piorkowski, MD Germany Mark Pitney, MBBS Australia Aleksey Protopopov, MD Russia Đeiti Prvulović, MD Croatia Maria Radu, MD, PhD Denmark Tomasz Rakowski, MD, PhD

Michael J. Rinaldi, MD, FACC USA Jamil A. Saad, MD, FACC

Brazil

Poland

Katherine Shreyder, MD, PhD Russia Andre R. Simon, MD, PhD United Kingdom Pieter Smits, MD, PhD The Netherlands Grzegorz Smolka, MD, PhD Poland Paul A. Sobotka, MD, FACC USA Helle Søholm, MD, PhD Denmark Philipp Sommer, MD Germany Dace Sondore, MD Latvia Jong-Min Song, MD, PhD South Korea Karlis Strenge, MD Latvia Gunnar Tepe, MD Germany Pim A.L. Tonino, MD, PhD The Netherlands Etsuo Tsuchikane, MD, PhD Japan Kazushi Urasawa, MD, PhD Japan BJL Van den Branden, MD, PhD The Netherlands Jan Van der Heyden, MD, PhD The Netherlands Robert A. Vogel, MD, FACC USA Szilard Voros, MD, FACC USA Kristian Wachtell, MD, PhD, FACC Denmark Darren L. Walters, MBBS, MPhil Australia Timothy Watson, MD New Zealand Steven K. White, BSc, MBChB United Kingdom Andrew Wilson, MBBS, PhD Australia Adam Witkowski, MD, PhD Poland Wojciech Wojakowski, MD, PhD

Poland Lucian Zarma, MD

Romania

SUNDAY, MARCH 1

7:00 – 10:00 AM MORNING SESSION

SOLACI SESSION



STEMI in Latin America: Challenges to Match Established Standards of Care Chairman:

Jorge Belardi, MD, FACC

STEMI: Stent for Life Program in Argentina Jorge Belardi, MD, FACC

The New Paradigm in the Treatment of Acute MI Luis A. Guzmán, MD, FACC

STEMI in Brazil: National Registries Jamil A. Saad, MD, FACC

Wearable Cardiac Defibrillators as a Bridge to ICD Post STEMI: What is the Evidence behind It? Diego F. Belardi, MD

AUSTRALIA/ NEW ZEALAND SESSION



Patrick Kay, MD, PhD

Controversies in the Use of FFR Andrew Wilson, MBBS, PhD

Treating Shock in the Elderly David Clark, MBBS

Radiation in the Cathlab: Angles, Projections, Positions – Do They Really Matter? Mark Pitney, MBBS

Necessity is the Mother of Invention Timothy Watson, MD Hypertension: Is There Still Room for a Nonpharmacological Approach? Patrick Kay, MD, PhD

Initial Experience with the Lotus Transcatheter Aortic Valve Implantation System: What Do Newer Generation Devices Bring to the TAVI Table? Darren L. Walters, MBBS, MPhil

RUSSIAN SESSION



Evgeny Merkulov, MD, PhD

Current Situation with LAA Closure Procedures in Russia: Experience with Complex LAA Closure Cases Evgeny Merkulov, MD, PhD

Grace-score Predicts Short and Long-term Mortality but Overestimates the Mortality Risk in ACS Patients Treated with PCI of LM Stenosis Katherine Shreyder, MD, PhD

Fractional Flow Reserve Measurement for Decision Making in Multivessel Flow and Diffuse Coronary Artery Disease Vsevolod Mironov, MD

Hybrid and Pure Endovascular Approaches in Patients with Aortic Dissections and Aneurysms Aleksey Protopopov, MD, PhD

How to Improve Support during CTO PCI Aleksander G. Osiev, MD, PhD

3:30 – 6:00 PM AFTERNOON SESSION

AMERICAN SESSION I: TAVR SESSION, PART I



Chairmen: Michael J. Mack, MD, FACC, and Augusto D. Pichard, MD, FACC

Global Results of TAVR Martin B. Leon, MD, FACC

Current Status of TAVR in US and Future Prospects; Update on the PARTNER Trials; US TVT Registry Michael J. Mack, MD, FACC

Outcomes on Inoperable Patients Raj Makkar, MD, FACC

CoreValve: Pros and Cons Augusto D. Pichard, MD, FACC

Patient Selection for TAVR Augusto D. Pichard, MD, FACC

Alternative Access for TAVR Michael J. Mack, MD, FACC

Preventing Vascular Complications Samir Kapadia, MD

Conscious Sedation for TAVR Augusto D. Pichard, MD, FACC

AV Block and PPM after TAVR Raj Makkar, MD, FACC

TAVR for Pure AR Augusto D. Pichard, MD, FACC

AR Complicating TAVR: How to Prevent and How to Treat Samir Kapadia, MD

Transcatheter Mitral Valve Innovations, Part I Brian T. Bethea, MD

In celebration of our 30th anniversary, each day we will look back over the past 30 years including video of live cases, slide presentations from past meetings, and a little bit of nostalgia.

MONDAY, MARCH 2

7:00 – 10:00 AM MORNING SESSION

AMERICAN SESSION II

New Aortic Valve Devices Michael J. Mack, MD, FACC

MINI-SYMPOSIUM ON NEUROPROTECTION

Stroke in TAVR: Is it a Deal Breaker? Samir Kapadia, MD

Carotid Artery Compression Theory Robert S. Schwartz, MD, FACC

DWI MRI Lesions as Surrogates of Cognitive Dysfunction Kevin Abrams, MD

Impact of MRI Methodology on DWI MRI Lesion Volume Measurements and Statistical Implications Szilard Voros, MD, FACC

Neuroprotection: Importance of Covering All Three Cerebral Vessels; Lessons from DEFLECT 1 and 2 Andreas Baumbach, MD

Cerebral Protection Devices: Deflection vs. Capture; Pros and Cons Jeffrey W. Moses, MD, FACC Update on Keystone Heart Clinical Program and Results Alexandra Lansky, MD, FACC

MR and TAVR Augusto D. Pichard, MD, FACC

Valve in Valve for Degenerated Bioprosthetic Aortic and Mitral Valves Samir Kapadia, MD

Transcatheter Mitral Innovations, Part II Michael J. Mack, MD, FACC

3:30 - 6:00 PM AFTERNOON SESSION

KOREAN SESSION



Chairman: Seung-Jung Park, MD, PhD, FACC

Optimal Stenting Strategy for Bifurcation Coronary Lesions: Lessons from the CROSS and PERFECT Trials Young-Hak Kim, MD, PhD

Changing Paradigm in Bifurcation Intervention Using the Contemporary DES: Lessons from the Korean Bifurcation Registry Hyo-Soo Kim, MD, PhD

Temporal Changes of PCI vs. CABG for Left Main Disease Seung-Jung Park, MD, PhD, FACC

Atherosclerotic Burden and its Clinical Impact of Asymptomatic Diabetes According to Risk Stratification Seung-Whan Lee, MD, PhD

Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation for Off-Label vs. On-Label Indication Duk-Woo Park, MD, PhD CT-derived Hemodynamic Assessment: Current and Future Applications Bon-Kwon Koo, MD, PhD, FACC

3D Echocardiography-guided Percutaneous Transcatheter Closure of Atrial Septal Defect Jong-Min Song, MD, PhD

Current TAVI: SAPIEN XT vs. Core Valve Seung-Jung Park, MD, PhD, FACC

BALKAN SESSION



Chairmen: Marko Noc, MD, PhD, and Sasko Kedev, MD, PhD, FACC

Stroke Prevention in the Hands of Interventional Cardiologists? Marko Noc, MD, PhD

Wrist Access (Radial and Ulnar) as a Primary Approach for Carotid Artery Stenting Sasko Kedev, MD, PhD, FACC

TAVR in the Balkans Matjaz Bunc, MD, PhD

STEMI Cooling after CHILL MI: Case Closed? Marko Noc, MD, PhD

Differences in sVCAM-1 in Patients Undergoing Stenting and Paclitaxel-coated Balloon Đeiti Prvulović, MD

Cardiogonimetry: Do we need Another Non-invasive Diagnostic Method for Suspected CAD in Women Prior to Coronary Angiography? Hrvoje Pintarić, MD, PhD

TUESDAY, MARCH 3

7:00 – 10:00 AM MORNING SESSION

SCANDINAVIAN SESSION

Chairmen:

Andrejs Erglis, MD, PhD, FACC, M. Pauliina Margolis, MD, PhD, and Kari I. Saunamäki, MD, PhD

Optimal Uptake Area for the STEMI Network: Time for a Change? Perspectives from a Single MEGA Center Peter Clemmensen, MD, DMSc

Primary PCI in Latvia: Lessons from Registry of Latvia Acute Coronary Syndrome Karlis Strenge, MD, PhD

How to Improve the Present Good Outcome of STEMI? Looking for High-risk Subgroups Kari 1. Saunamäki, MD, PhD

Implications of Left Ventricular Hypertrophy in STEMI Patients Treated with Primary PCI Thomas Engstrøm, MD, DMSci, PhD

Cause and Time of Death Associations in Patients Treated with Percutaneous Coronary Intervention for Non ST-Elevation Myocardial Infarction Kristian Wachtell, MD, PhD

Novel Technique for Distal LMCA Lesions Using DES and ABSORB: One-year Follow-up Dace Sondore, MD

Coronary OCT – Quo Vadis? Maria Radu, MD, PhD

The Nordic Dedicated Bifurcation Stent Study – Rationale and Design Jens Flensted Lassen, MD, PhD Follow-up Results of the Percutaneous Septal Sinus Shortening (the MVRx System) for the Treatment of Functional Mitral Regurgitation Andreis Erglis, MD, PhD, FACC

Transcatheter Mitral Valve Implantation: Experience from the First In-human Cases Nikolaj Ihlemann, MD, PhD, Lars Søndergaard, MD, DMSc, Susanne Holme, MD, and Peter Bo Hansen, MD

Renal Denervation after HTN3 Anne Kaltoft, MD, PhD

Primary PCI in Patients with STEMI and Pre-hospital Cardiac Arrest – Why Some People Arrest and Others Do Not Helle Søholm, MD

3:30 – 6:00 PM AFTERNOON SESSION

CENTRAL/EASTERN EUROPEAN SESSION I Urgent and Elective Coronary Revascularization



Chairmen: Dariusz Dudek, MD, PhD, Petr Kala, MD, PhD, and Jacek Legutko, MD, PhD

Acute Coronary Syndromes in 2015: Update on Logistics, Treatment, and First vs. Second Generation DES in High-risk ACS Patients: Katowice-Zabrze Registry of 2000 patients Wojciech Wojakowski, MD, PhD

Stent for Life Initiative Achievements in STEMI Patients in Europe and Beyond Petr Kala, MD, PhD

Stent for Life Initiative in Poland – Update on Logistics and Clinical Outcomes in STEMI and NSTE ACS Jacek Legutko, MD, PhD Change in the Landscape of Antiplatelet Treatment in ACS Tomasz Rakowski, MD, PhD

Bioresorbable Scaffolds for PCI in ACS – In-hospital and Long-term Outcomes Dariusz Dudek, MD, PhD

ACS in Patients Less Than 45 Years Old Robert J. Gil, MD, PhD

Stem Cells in CV Disease – We Need Second Generation Cell Products! Wojciech Wojakowski, MD, PhD

CENTRAL/EASTERN EUROPEAN SESSION II Coronary Revascularization in Stable Angina

Chairmen: Dariusz Dudek, MD, PhD, Jacek Legutko, MD, PhD, and Lucian Zarma, MD

IVUS-guided Bifurcation Stenting – New Insights from the BLAST and Other Studies Jacek Legutko, MD, PhD

Safety and Efficacy of the New Generation Bifurcation Dedicated Stent BiOSS LIM – Final Results of the POLBOS II Study Robert J. Gil, MD, PhD

Breaking the Limits or Just Breaking the Struts? One-year Clinical and Angiographic Outcomes after Implantation of Bioresorbable Scaffolds in Coronary Bifurcation Lesions Maciej Lesiak, MD, PhD

First In-man Experience with New Microcatheter NovaCross™ in Chronic Total Occlusions Leszek Bryniarski, MD, PhD

TUESDAY continued

WEDNESDAY, MARCH 4

One-year Clinical and Angiographic Outcomes after Implantation of Bioresorbable Scaffolds in Chronic Total Occlusions Maciej Lesiak, MD, PhD

Coronary Revascularization before TAVI / Mitral Interventions – When and How? Dariusz Dudek, MD, PhD

Hybrid Coronary Revascularization for Multivessel Disease – Should it be a Common or Niche Strategy? New Insights from the HYBRID Trial Michal Hawranek, MD, PhD

Hybrid Coronary Revascularization for Multivessel Disease – Would Novel Antiplatelet and Antithrombotic Compounds Become a Mainstream Strategy for the Future? Krzysztof Milewski, MD 7:00 – 10:00 AM MORNING SESSION



The Future of TAVR Martin B. Leon, MD, FACC

Stem Cells: State of the Union Timothy D. Henry, MD, FACC

What Makes Cents (sic) for Treating Superficial Femoral Disease in 2015: Balloons, Stents, or Atherectomy? Mark W. Burket, MD, FACC

Sympathetic Denervation: Are the Data Right and the Doctor Wrong, or Vice Versa? Paul A. Sobotka, MD, FACC

PFO Closure: Are the Data Right and the Doctor Wrong, or Vice Versa? James R. Margolis, MD, FACC

Stable Angina: Are the Data

Right and the Doctor Wrong, or Vice Versa? Jeffrey W. Moses, MD, FACC

What is the Etiology of Arteriosclerosis: A DNA Analysis of Receptive Plaque Richard R. Heuser, MD, FACC

Left Atrial Appendage Closure Michael J. Rinaldi, MD, FACC Precision Phenotyping and Panomics for Biomarker and Drug Target Discovery: The GLOBAL Study Szilard Voros, MD, FACC

New Era in Lipid Management? Robert A. Vogel, MD, FACC

Dual or Triple Therapy for PCI Patients with Atrial Fibrillation Kurt Huber, MD, FACC

3:30 – 6:00 PM AFTERNOON SESSION

ORAL ABSTRACT SESSION I

JAPANESE SESSION



Chairmen: Osamu Katoh, MD, Hideo Nishikawa, MD, PhD

CTO-PCI: Past, Present and the Future Osamu Katoh, MD

CTO-PCI Registry in Japan Etsuo Tsuchikane, MD, PhD

My Style of EVT Kazushi Urasawa, MD, PhD

Recent Japanese Clinical Trials Hideo Nishikawa, MD, PhD

BRITISH SESSION



Target vs. Total Revascularization in PCI Charles Ilsley, MD

Acute Physiologic Measurements during Primary PCI to Predict Final Infarct Size Andreas Baumbach, MD

THURSDAY, MARCH 5

Fusion Mapping of Physiology and Anatomy (IVUS/Angiography) to Guide Clinical Decision Making Justin Davies, MD, PhD

Acute Cardiac Support: Current Role of LVAD and VA ECMO Andre R. Simon, MD, PhD

Human Factors in Acute Cardiac Care Mark Mason, MD

CRRISIS in the Cath Lab: Simulated Emergency Training David Gareth Jones, BSc(Hons), MBBS, MD(Res)

The Future of Infarct Imaging? ...New Insights from PET-MRI Steven K. White, BSc, MBChB

Should We Lose Faith in Renal Denervation? Early Findings Evaluating the Reduction in Blood Pressure in Pharmacological Controlled Subjects Undergoing Distal and Branch Renal Artery Denervation Justin Davies, MD, PhD

7:00 – 10:00 AM MORNING SESSION





Chairmen: Nicolaus Reifart, MD, FACC, and Gerald S. Werner, MD, PhD, FACC

Concepts for the Treatment of SFA In-stent Restenosis Hans Krankenberg, MD

Ascending Aorta: A New Field for Endovascular Treatment? Hans Krankenberg, MD

Cardiac MRI 20 Years Later Michael Pieper, MD

25 Years Experience in CTO PCI: 5-Years Inspired by EURO-CTO-CLUB Markus Meyer-Gessner, MD

Early and Late Management of Aortic Dissection Christoph A. Nienaber, MD, PhD

Monitored Euro-CTO Registry: A New Concept to Improve Quality Data Nicolaus Reifart, MD, FACC

Severe Calcification as a Predictor of Outcome of DCB Treatment in Peripheral Arteries: Results of a Blinded Core Lab Analysis and a Possible Way to Overcome this Issue with Atherectomy, BTK Study Concept Gunnar Tepe, MD

The Impact of CTO on Mortality in STEMI PCI: Results of a Prospective Multicentre Study of More than 12,000 Patients (FITT-STEMI) Gerald S. Werner, MD, PhD, FACC

Long-term Patency as the Ultimate Challenge for CTO PCI: The Potential of Bioabsorbable Scaffolds Gerald S. Werner, MD, PhD, FACC

A LITTLE BIT OF EP



Fighting Sudden Cardiac Death Over the Last Three Decades: Progress and Challenges Gerhard Hindricks, MD, PhD

Heart Failure and Cardiac Implants: Resynchronization and Novel Approaches Christopher Piorkowski, MD

Catheter Ablation of Ventricular Tachycardia in Patients with Organic Heart Disease: Can We Replace the ICD? Philipp Sommer, MD

3:30 – 6:00 PM AFTERNOON SESSION

ORAL ABSTRACT SESSION II

DUTCH SESSION

Chairman: Jacques J. Koolen, MD, PhD

Edwards Sapien XT vs Edwards Sapien 3 Guus Brueren, MD, PhD

Multivessel Disease Experience from FAME 1, 2, and 3 Pim A.L. Tonino, MD, PhD

Single Center Experience with Absorbable Stents: What is Our Indication? Jacques J. Koolen, MD, PhD

Paravalvular Leakage after TAVR Peter den Heijer, MD, PhD

Mitral Valve Clipping: An Update BJL Van den Branden, MD, PhD

THURSDAY continued

FRIDAY, MARCH 6

DES or BMS in Patients on Long-term Anticoagulants Who Need PCI? Willem Dewilde, MD

First European Experience with Novel Hypertension Treatment Jan Van der Heyden, MD, PhD

Which Patients Benefit from Bioreabsorbable Scaffolds? The Five-year Maasstad Hospital Experience and Introduction to the Multicenter COMPARE-ABSORB Trial Pieter Smits, MD, PhD

The Heart of Women: Playing Hard to Get? Yolande Appelman, MD, PhD

MicroRNA's Provide an Optimal Target to Change Cardiovascular Function Pieter A. Doevendans, MD, PhD

Final Two-year Results of the APPOSITION III Study Evaluating the Use of the STENTYS Self-apposing Stent for the Treatment of ST-Segment Elevation Myocardial Infarction in the Setting of Primary PCI Karel T. Koch, MD, PhD 7:00 - 10:00 AM MORNING SESSION

CENTRAL/EASTERN EUROPEAN SESSION III Interventional Cardiology beyond Coronary Revascularization



Chairmen: Dariusz Dudek, MD, PhD, Andrzej Ochala, MD, and Adam Witkowski, MD, PhD

TAVI in Intermediate Risk Patients Adam Witkowski, MD, PhD

Feasibility and Clinical Outcomes of TAVI in Difficult Subsets: Bicuspid Aortic Valve, Valve-in-valve Implantations Radoslaw Parma, MD, PhD

Immediate and Long-term Outcomes after TAVI in Poland – POLTAVI Registry New Generation TAVI Dariusz Dudek, MD, PhD, Adam Witkowski, MD, PhD

Incidence, Predictors and Outcome of VARC2-defined Acute Kidney Injury after TAVI Andrzej Ochala, MD

Percutaneous Treatment of Mitral Valve Dariusz Dudek, MD, PhD

Transcatheter Closure of Paravalvular Leaks Grzegorz Smolka, MD, PhD The ROX Coupler:

Creation of a Fixed Central Arterial-Venous Anastomosis for the Treatment of Systemic Arterial Hypertension Adam Witkowski, MD, PhD

Is There a Place for New Generation Percutaneous Devices Designated for the Treatment of Resistant Hypertension? Krzysztof Milewski, MD, PhD

Safety and Performance of Urinary Bladder Electrical Stimulation in Acute Decompensated Heart Failure Andrejs Erglis, MD, PhD

Advanced Techniques for Recanalization of Peripheral Arteries Stanislaw Bartus, MD, PhD

Discussion & Summary

LOCATION

The Westin Snowmass Resort Snowmass Village, Colorado

REGISTRATION

Physician/Industry \$1,050 through January 16, 2015 \$1,250 after January 16, 2015

Resident/Fellow/Nurse \$550 through January 16, 2015 \$750 after January 16, 2015

Please make checks payable to Promedica International CME in US dollars drawn on a US bank. Visa, MasterCard, American Express and Discover cards are also accepted.

Please register online at www.promedicacme.com. If you prefer, you may complete the form below and mail or fax it to:

Promedica International CME 300 Carlsbad Village Drive, Suite 108A-326 Carlsbad, CA 92008 Tel: (760) 720-2263 Fax: (760) 720-6263 Email: Lsteigerwald@promedicacme.com

REFUNDS

All cancellations must be submitted in writing and refunds will be subject to a \$100 administration charge. Cancellations cannot be accepted over the telephone. Refunds will not be available after January 16, 2015.

HOTEL ACCOMMODATIONS

A block of rooms has been reserved at the Westin Snowmass Resort and in limited quantities at the adjacent Wildwood Snowmass. Please contact the hotel directly for room reservations at 800-525-9402 or 970-923-3520. In order to receive the special rates below, you must mention the Interventional Cardiology 2015 symposium. Reservations must be received by the Westin Snowmass Resort no later than end of business day, February 6, 2015.

Special rates for Interventional Cardiology 2015 participants are below. Please note that a resort fee and applicable taxes will be added to the nightly rates.

\$345 Westin Alpine Room (king) \$375 Westin Deluxe Pinnacle Room

- (2 queens or king)
- \$395 Westin Premium Pinnacle Room (2 queens or king) aka "Slopeview"
- \$199 Wildwood Room (2 doubles or king)

All reservations must be guaranteed and accompanied by a deposit of 25% of the total room night revenue at the time of booking. The balance is due 30 days prior to arrival.

CONFERENCE PRODUCED BY PROMEDICA INTERNATIONAL CME

Look for continuous updates on our website at www.promedicacme.com

Interventional Cardiology 2015: 30 [™] Annual International Symposium March 1–6, 2015					
REGISTRATION	Physician/Industry □\$1,050 Through January 16, 2015 □\$1,250 After January 16, 2015		Resident/Fellow/Nurse □ \$550 Through January 16, 2015 □ \$750 After January 16, 2015		
PAYMENT All fees	in US dollars drawn on US banks:	□ Check Enclosed	□ Visa/MasterCard	□ American Express	Discover Card
CREDIT CARD NUMBER	!	EXPIRATION DATE	SIGNATURE		
FIRST/LAST NAME				□ MD	RN CCP
HOSPITAL/COMPANY					
MAILING ADDRESS					
CITY/STATE/ZIP/COUNT	RY				
TELEPHONE		FAX			
EMAIL ADDRESS		SPE	CIALTY		
300 Carlsbad V	ald, Promedica International illage Drive, Suite 108A-326, wald@promedicacme.com		18 Tel: (760) 720-2	2263, Fax: (760) 720	-6263

Promedica International CME 300 Carlsbad Village Drive, Suite 108A-326 Carlsbad, CA 92008 HERE'S WHAT THEY'RE SAYING

One of the best programs available in interventional cardiology!

Great international view of different approaches to disease management.

The faculty was exceptional...the enthusiasm contagious!

Excellent content and a most thorough presentation and discussion of the important issues in interventional medicine.

This meeting is one of the best in the world for international networking and invasive cardiology!

Interesting and inspiring talks and very engaged discussions with top shots in a perfect environment.

Presort Standard U.S. Postage PAID Permit 1948 San Diego CA